Tweet

@escardio

@escardio

@escardio

@escardio

@escardio

More from @HanCardiomd

Henry Han, MBBS, MD

@HanCardiomd

4 Nov

@ESC_Journals

Multimodality imaging in patients with HFpEF: an expert consensus document of the European Association of Cardiovascular Imaging #EACVI #MMI #HFpEF academic.oup.com/ehjcimaging/ad… @ESC_Journals @Cosyns @alessia_gimelli @ThorEdvardsen @VDelgadoGarcia @bogdan_popescu1 @JaeKOh2

@EACVIPresident

This expert consensus document from the #EACVI provides recommendations regarding how to determine elevated LV filling pressure in the setting of suspected #HFpEF and how to use multimodality imaging to determine specific aetiologies in patients with HFpEF @EACVIPresident

📌Mechanisms of LV diastolic dysfunction include impaired relaxation, attenuated restoring forces, and increased passive elastic stiffness that leads to elevated LV filling pressure

📌The presence of LV hypertrophy and dilated LA provides support for the #HFpEF diagnosis

Read 5 tweets

Henry Han, MBBS, MD

@HanCardiomd

30 Aug

@ESC_Journals

Iron deficiency as a therapeutic target in heart failure - new evidence, new guidelines

New evidence from AFFIRM-AHF ‒ implications for clinical practice with ⬆️QoL
#ESCCongress @ESC_Journals @escardio @ShelleyZieroth @hvanspall @DrNasrien @SilCastelletti @DrMarthaGulati

@ESC_Lavinia

New evidence from AFFIRM-AHF ‒ implications for clinical practice on cost effectiveness and QoL

#ESCCongress @ESC_Lavinia @escardio @ESCardioNews @ShelleyZieroth @JavedButler1 @rachkataria @AndreasGevaert @AndrewJSauer @pabeda1 @BSHeartFailure @FH_Verbrugge @DrRyanPDaly

@JavedButler1

Very insightful presentation by @JavedButler1 on New evidence from meta-analyses ‒ lessons to learn on the benefits of intravenous ferric carboxymaltose in HF

#ESCCongress @JavedButler1 @DrNasrien @MihaiTrofenciuc @pabeda1 @AndrewJSauer @NMHheartdoc @hvanspall @MajaCikes

Read 5 tweets

Henry Han, MBBS, MD

@HanCardiomd

29 Aug

@escardio

Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt? - Joint with (ISCP)

Prevention of thromboembolism in COVID-19
#ESCCongress @escardio @ESC_Lavinia @Steph_Achenbach @susannaprice @mmamas1973 @fhussain73 @DrJennHaythe md

@escardio

Recommendation for thrombophylaxis in COVID19

#ESCCongress @escardio @ESCardioNews @ESC_Lavinia @mmamas1973 @fhussain73 @susannaprice @JJcolemanMD @DrJennHaythe @PeterHotez @VirusesImmunity @bchTicTocDoc @AnastasiaSMihai

@escardio

COVID-19 #myocarditis and myocardial injury: active participant or innocent bystander?
#ESCCongress
@escardio @DrJennHaythe @AnastasiaSMihai @CMichaelGibson @mmamas1973 @EricTopol @ErinMichos @DBelardoMD @fhussain73 @VirusesImmunity @fhussain73 @pabeda1 @JGrapsa

Read 8 tweets

Henry Han, MBBS, MD

@HanCardiomd

29 Aug

@lamcardio

Exploring the cardiorenal benefits of MR antagonism in CKD and T2D

📌Finerenone - Novel , selective , non- steroidal MRA

#ESCCongress @lamcardio @BiykemB @MihaiTrofenciuc @pabeda1 @AndrewJSauer @MeralKayikcoglu @ErinMichos @DrMarthaGulati @DavidLBrownMD @JamalRanaMD

@CMichaelGibson

Finerenone has a favorable safety profile across a wide dose range in patients with CKD and T2DM receiving a RAS blocker
#ESCCongress

@CMichaelGibson @JamalRanaMD @DrMarthaGulati @AnastasiaSMihai @onco_cardiology @DavidLBrownMD @biljana_parapid @AndrewJSauer @ShelleyZieroth

@escardio

New promising player to protect Kidney and Heart in CV Medicine

#ESCCongress @escardio @ESC_Lavinia @TheLancetEndo @kidney_boy @Nephro_Sparks @ASNKidney @NephJC @DBelardoMD @NephroGuy @lipiddoc @AnastasiaSMihai @MihaiTrofenciuc @MiguelCamafort @Steph_Achenbach

Read 5 tweets

Henry Han, MBBS, MD

@HanCardiomd

28 Aug

@escardio

FIGARO -DKD

FIGARO-DKD Finds Finerenone Offers CV Benefits in Mild to Moderate Kidney Disease With T2D; Cuts HF Hospitalization 29% @escardio #ESCCongress @JJheart_doc @AnastasiaSMihai @ESC_Journals @ShelleyZieroth @mmamas1973 @hvanspall @JavedButler1 @DrNasrien @aayshacader

@escardio

A statistically significant 13% lower risk among those treated with finerenone, a benefit that was driven by a reduction in HHF (HR 0.71; 95% CI 0.56-0.90)

@escardio #ESCCongress @ShelleyZieroth @hvanspall @mmamas1973 @AnastasiaSMihai @DrNasrien @lamcardio @JavedButler1

@escardio

The combined patient-level analysis of FIGARO-DKD and FIDELITY-DKD included 13,171 patients with #T2DM of whom 40% had preserved kidney function as defined by the eGFR ≥ 60 mL/min/1.73 m2 but elevated UACR

@escardio #ESCCongress @ESC_Journals @lamcardio @FaiezZANNAD

Read 4 tweets

Henry Han, MBBS, MD

@HanCardiomd

28 Aug

@JavedButler1

SGLT2 Inhibitor HFpEF Data: From Context to Clinical Pearls
By @JavedButler1

#ESCCongress @lamcardio @BSHeartFailure @JJheart_doc @ESC_Journals @ESC_Lavinia @escardio @MKIttlesonMD @ShelleyZieroth @hvanspall @mmamas1973 @aayshacader @pabeda1

@ESC_Lavinia

The drug ⬇️ the risk of ≥ 50% ⬇️ in eGFR or renal death in EMPEROR-Reduced (HR 0.51; 95% CI 0.33-0.79), but not in EMPEROR-Preserved (HR 0.95; 95% CI 0.73-1.24) #ESCCongress @ESC_Lavinia @escardio

@escardio

Prior outcomes Trials in #HFpEF and Traditional Mx of HFpEF
What makes EMPEROR-P difference from them?
#ESCCongress @escardio @ESC_Lavinia @lamcardio @JJheart_doc @CMichaelGibson @biljana_parapid @mmamas1973 @ShelleyZieroth @aayshacader @AndrewJSauer @DrRyanPDaly @RyanTedfordMD

Read 6 tweets

Share this page!

Henry Han, MBBS, MD

Try unrolling a thread yourself!

More from @HanCardiomd

Henry Han, MBBS, MD

Henry Han, MBBS, MD

Henry Han, MBBS, MD

Henry Han, MBBS, MD

Henry Han, MBBS, MD

Henry Han, MBBS, MD

Did Thread Reader help you today?

Like this author's thread?